Median relapse free survival disease free survival. Medical search. Frequent questions

Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. (springer.com)
It describes and discusses data on locoregional treatment, chemo-, antibody- and immunotherapy and tries to select individual patients for whom a multidisciplinary treatment approach with curative intention might be an option to achieve long-term survival. (springer.com)
It is of great interest to define subgroups of patients suffering from this heterogeneous disease that might benefit from different treatment strategies. (springer.com)
One special subgroup comprises patients with limited tumor spread lying between localized early breast cancer and disseminated metastatic cancer, termed oligometastatic disease. (springer.com)
For example in colorectal cancer, long-term remission of oligometastatic lung or liver disease is achievable in a subgroup of patients and this strategy is part of established guidelines [ 4 ]. (springer.com)
Additionally, a plateau in progression-free survival (PFS) and overall survival (OS) Kaplan-Meier curves may reflect the curative potential of a cancer treatment and serve as a surrogate for a subpopulation of patients with characteristic features. (springer.com)
In a publication on 225 patients, primarily with Hb SS disease, data shows that even though 60% of patients were taking hydroxyurea, the median survival age was only 48 years. (nih.gov)
In another paper, the cumulative survival in 150 adults was followed from 2003 to 2016 and patients were screened for heart, lung, and kidney disease. (nih.gov)
Five of eight patients engrafted and only two remain free of SCD. (nih.gov)
Ten of twelve patients engrafted, but only six remain free of SCD. (nih.gov)
In a Phase 1/2 trial, in solid tumor patients refractory to standard therapy, response evaluation showed disease stabilization in a majority of patients. (wikipedia.org)
Eligible patients were required to have relapsed refractory multiple myeloma. (wikipedia.org)
Patients received melphalan flufenamide 40 mg intravenously on day 1 and dexamethasone 40 mg orally (20 mg for patients ≥75 years of age) on day 1, 8, 15 and 22 of each 28-day cycle until disease progression or unacceptable toxicity. (wikipedia.org)
Objectives: Describe and evaluate the perception of the prejudice against the disease and its impact on the quality of life of patients with sickle cell disease. (scielo.br)
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center . (mdanderson.org)
This trial shows that the combination of ponatinib and blinatumomab produces high rates of complete molecular response, which reduces the chances that patients will relapse and increases the likelihood that they will be disease-free. (mdanderson.org)
After chemotherapy treatment and disease remission, patients traditionally undergo a stem cell transplant to reduce the chance of disease recurrence. (mdanderson.org)
However, as the outcomes for patients with low- and intermediate-risk disease are similar, these categories have been collapsed into one and considered as low-risk disease. (nature.com)
Combination therapies, in particular those using 3 and 4 drugs, have improved response rates and survival outcomes for patients with relapsed or refractory multiple myeloma. (onclive.com)
For patients who experience early relapse, data from the phase 3 IKEMA study (NCT03275285) supported the use of isatuximab-irfc (Sarclisa), a CD38-directed cytolytic antibody, plus carfilzomib (Kyprolis) and dexamethasone (Isa-Kd) in patients who received 1 to 3 prior lines of therapy. (onclive.com)
Among 161 patients (pts) included in the study, with a median age of 53 years (17-72), 98 pts (60.9%) received a reduced-intensity conditioning (RIC), 36 pts (22.4%) reduced-toxicity conditioning (RTC), 18 pts (11.1 %) sequential conditioning, and 9 pts (5.6%) myeloablative conditioning (MAC). (confex.com)
On September 1, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and for treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older. (fda.gov)
Using the per protocol definition of event-free survival (EFS), estimated median EFS was 17.3 months for patients receiving gemtuzumab ozogamicin vs. 9.5 months for those receiving chemotherapy alone, with hazard ratio of 0.56 (95% CI: 0.42, 0.76). (fda.gov)
Patients with no evidence of disease progression or significant toxicities after induction received continuation therapy as outpatients with up to 8 courses of treatment including gemtuzumab ozogamicin 2 mg/m2 on day 1, every 4 weeks. (fda.gov)
Estimated median overall survival (OS) was 4.9 months for patients receiving gemtuzumab ozogamicin vs. 3.6 months for those receiving BSC, with hazard ratio of 0.69 (95% CI: 0.53, 0.90). (fda.gov)
The second trial, MyloFrance-1, a phase 2, single-arm, open-label study, included 57 patients with CD33-positive AML in first relapse. (fda.gov)
Furthermore, these three genes predicted overall survival and recurrence‑free survival in patients with ACC from the TCGA cohort. (cancerindex.org)
Patients' characteristics and information regarding disease and transplant are summarized in Table 1 . (haematologica.org)
Patients', disease and transplant characteristics. (haematologica.org)
There was a trend for a lower incidence of relapse for patients in complete remission (HR=0.49, 95%CI: 0.22-1.07, P =0.07). (haematologica.org)
Objectives Patients with classical Hodgkin lymphoma (cHL) relapsing after second-line therapy have a dismal prognosis and novel approaches are required for this patient group. (uni-koeln.de)
Based on promising (pre-)clinical data and the favourable toxicity profile, we performed a phase II clinical trial with the JAK inhibitor ruxolitinib in patients with relapsed or refractory cHL (r/r cHL). (uni-koeln.de)
At 5 years, 89% of patients with treatment-naive and relapsed or refractory CLL/SLL achieved a complete response or partial response to ibrutinib, including some patients with high-risk disease. (ascopost.com)
Patients treated earlier in the course of disease had longer progression-free survival as well. (ascopost.com)
Our data also suggest that starting treatment with ibrutinib in CLL/SLL rather than waiting until after patients have relapsed from chemotherapy has promising clinical potential for long-term progression-free and overall survival. (ascopost.com)
1 Two patient cohorts were followed: 31 treatment-naive patients and 101 patients with relapsed or refractory disease (24 with high-risk disease). (ascopost.com)
In general, treatment-naive patients were older and had more advanced Rai stage disease, whereas those with relapsed or refractory disease were more likely to have been heavily pretreated as well as to have bulky disease and higher levels of beta-2 microglobulin. (ascopost.com)
Median time on study was 62 months for treatment-naive patients and 49 months for those with relapsed or refractory disease. (ascopost.com)
Almost two-thirds of treatment-naive patients remained on therapy, compared with less than one-third of those with relapsed or refractory disease. (ascopost.com)
Venetoclax may be an option for high-risk patients who relapse or are refractory to ibrutinib. (ascopost.com)
At 5 years, progression-free survival was 92% in treatment-naive patients and 43% in those with relapsed or refractory disease. (ascopost.com)
What is new is that median progression-free survival was 52 months in relapsed/refractory patients, and this is impressive," revealed Dr. O'Brien. (ascopost.com)
In the largest clinical trial to date of immune checkpoint inhibitors for mesothelioma, patients treated with nivolumab-either alone or in combination with ipilimumab-posted impressive response rates and survival outcomes, according to data presented at the 2017 American Society of Clinical Oncology Annual Meeting. (aacrjournals.org)
Given an historical 12-week disease control rate of less than 30% with existing treatments, oncologists are enthusiastic about having a more effective therapeutic option for patients with this rare, hard-to-treat cancer of the lining of the lungs, typically associated with asbestos exposure. (aacrjournals.org)
He described results from the first 108 participants of the phase II MAPS-2 study, which enrolled 125 patients with malignant pleural mesothelioma who had experienced disease relapse after receiving at least two prior treatments. (aacrjournals.org)
The disease remained stable in another quarter of patients treated with either regimen. (aacrjournals.org)
Merck), John's group and an independent team led by Hedy Lee Kindler , MD, from the University of Chicago Medical Center in Illinois, each reported new data at the ASCO meeting showing that tumors with higher PD-L1 expression responded better to treatment, leading to prolonged survival in small cohorts of patients. (aacrjournals.org)
Ultimately, only placebo-controlled trials may demonstrate the true benefit of immunotherapy for relapsed mesothelioma, especially because open-label trials like MAPS-2 tend to be biased by patients who are heavily pretreated yet fit enough for enrollment. (aacrjournals.org)
According to John, these patients often present with indolent disease and do well for months regardless of treatment. (aacrjournals.org)
These patients are designated as having limited-stage disease (LD). (cancer.gov)
1 ] Patients with tumors that have spread beyond the supraclavicular areas are said to have extensive-stage disease (ED). (cancer.gov)
Investigations of patients with suspected SCLC focus on confirming the diagnosis and determining the extent of the disease. (cancer.gov)
About 10% of the total population of SCLC patients remains free of disease during the 2 years from the start of therapy, which is the time period during which most relapses occur. (cancer.gov)
Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
In this retrospective analysis, the investigators assessed the impact of the number of induction and consolidation cycles and disease status on the success of allo-HCT in 3,113 patients with AML from 2008 to 2019. (ascopost.com)
A total of 1,473 patients with a median age of 47 years received myeloablative conditioning, and 1,162 patients with a median age of 63 years received reduced-intensity conditioning. (ascopost.com)
Compared with the poor outcomes of patients who received allo-HCT during refractory (active) disease, the outcomes of patients who received more than one induction cycle to achieve complete remission is somewhat better but remains unsatisfactory. (ascopost.com)
A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology. (medicaldaily.com)
PARIS - April 19, 20 21 - Today, the European Commission (EC) approved Sarclisa ® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. (sanofi.com)
In June 2020, Sanofi announced Sarclisa received EC approval in combination with another standard of care regimen, pomalidomide and dexamethasone (pom-dex), for the treatment of adult patients with relapsed and refractory MM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. (sanofi.com)
This approval is based on data from the Phase 3 IKEMA study, a randomized, multi-center, open label clinical trial that enrolled 302 patients with relapsed MM across 69 centers spanning 16 countries. (sanofi.com)
Sarclisa combination therapy reduced the risk of disease progression or death by 47% (hazard ratio 0.531, 99% CI 0.318-0.889, p=0.0007) versus standard of care Kd alone in patients with MM. (sanofi.com)
Prognostic markers for survival in patients with pancreatic ductal adenocarcinoma. (muni.cz)
The Auckland Advanced Breast Cancer Review (AABC) was a review of patients diagnosed with advanced inoperable/metastatic breast cancer (ABC) within the Auckland region of New Zealand, commissioned in response to a Breast Cancer Registry report (BCFNZR) that showed poor and inequitable survival outcomes. (hindawi.com)
Of the 388 patients that met inclusion criteria for this study, median overall survival (medOS) was 18.9 months in the total population, with no difference between patients with de novo metastatic disease (dnMBC -18.9 m) and recurrent metastatic disease (rMBC -18.7 m). (hindawi.com)
While treatment uptake and survival outcomes were generally comparable across ethnicity and district health boards, dnMBC survival outcomes were considerably poorer than expected, earmarking this subset of patients with ABC for more in-depth research. (hindawi.com)
Interestingly, the metastasis free interval (mFI: 30 months) amongst patients who developed metastatic relapse after early breast cancer was similar to international standards. (hindawi.com)
This inequity was reflected in the BCFNZR, where Maori had the poorest survival outcomes amongst patients with ABC compared to all other ethnicities in NZ, with a medOS of only 12.8 months. (hindawi.com)
1-3 Current treatment cures only a minority of AML patients and less than 20% have a long-term survival. (dovepress.com)
Although the impact of FLT3 -ITD mutation is unclear in the context of venetoclax-azacitidine treatment, 6 the negative impact of FLT3 -ITD on survival of AML patients treated with ICT is well established. (dovepress.com)
1 , 7-9 In the 2017 European Leukemia network (ELN) classification, prognosis of FLT3 -ITD mutation on the survival of AML patients was dependent on the co-occurrence of the nucleophosmin 1 gene mutation ( NPM1 mut) and the FLT3 -ITD mutation burden. (dovepress.com)
Treatment with the immunotherapy Opdivo for relapsed, malignant mesothelioma may represent a useful choice for patients with minimal therapy options. (curetoday.com)
Immunotherapy with Opdivo (nivolumab) may be a beneficial treatment for patients with malignant mesothelioma whose disease progressed on first-line therapy, trial results demonstrated. (curetoday.com)
Findings from the CONFIRM trial were published in Lancet Oncology , which represents "the first phase 3 clinical trial to have demonstrated an improvement in survival for patients with relapsed mesothelioma," said Fennell, who was one of the researchers on this trial. (curetoday.com)
In the CONFIRM trial, researchers assessed data from 332 patients with relapsed, malignant mesothelioma. (curetoday.com)
Patients were followed up for a median of 11.6 months. (curetoday.com)
During the trial, patients received a median of six doses of Opdivo and four doses of placebo. (curetoday.com)
Patients assigned Opdivo had a median progression-free survival of three months compared with 1.8 months in those assigned placebo. (curetoday.com)
BEIJING--( BUSINESS WIRE )--American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL), which investigated the efficacy and safety of orelabrutinib in r/r MZL. (businesswire.com)
The journal concluded that orelabrutinib demonstrated high response rates with durable disease remission and was well tolerated in patients with relapsed or refractory MZL. (businesswire.com)
The majority of the enrolled patients had late-stage disease. (businesswire.com)
High response rates were consistent among patients with different MZL subtypes and those with negative disease prognostic factors at baseline. (businesswire.com)
On Dec. 25, 2020, orelabrutinib received conditional approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). (businesswire.com)
in 7 patients, disease recurred. (snmjournals.org)
Significant hypoxia was present in 58 patients (79%), and both the degree of hypoxia and the size of the hypoxic volume were independent predictive factors for survival ( 10 ). (snmjournals.org)
The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS ® (carfilzomib) and dexamethasone (Kd) lived 7.6 months longer than those treated with Velcade ® (bortezomib) and dexamethasone (Vd) (median OS 47.6 months for Kd versus 40.0 for Vd, HR = 0.79, 95 percent CI, 0.65 - 0.96). (amgen.com)
For an incurable disease like multiple myeloma, a major treatment goal for oncologists and hematologists is to help patients live as long as possible," said study co-author and investigator Meletios A. Dimopoulos, M.D., professor of Clinical Therapeutics at the National and Kapodistrian University of Athens , School of Medicine. (amgen.com)
The KYPROLIS clinical program continues to focus on providing solutions for physicians and patients in treating this frequently relapsing and difficult-to-treat cancer. (amgen.com)
KYPROLIS is available for patients whose myeloma has relapsed or become resistant to another treatment and continues to be studied in a range of combinations and patient populations. (amgen.com)
A phase 3 study evaluating subcutaneous (SC) daratumumab plus pomalidomide found that daratumumab plus pomalidomide and dexamethasone (D-Pd) significantly reduced the risk of progression or death by 37% in patients with relapsed/refractory multiple myeloma (RRMM) who had received more than or equal to 1 prior line of therapy versus pomalidomide alone, according to data to be presented at the virtual American Society of Hematology (ASH) conference. (pharmacytimes.com)
The patients were randomized 1:1 to Pd ± daratumumab SC, and stratification was based on International Staging System disease stage and number of lines of prior therapy. (pharmacytimes.com)
All patients were treated until disease progression or unacceptable toxicity, with the primary endpoint being progression free survival (PFS). (pharmacytimes.com)
A total of 304 patients from 12 European countries were randomized, with the median range being 67 years of age and 45%/33%/22% patients being ISS stage 1/2/3. (pharmacytimes.com)
With a median follow-up of 16.9 months, 99 patients have died, yet survival data are immature with ongoing follow-up occurring. (pharmacytimes.com)
In the clinical trial , treatment with both drugs also improved how long patients lived overall: a median of 2 years, compared with about 8 months for those treated with azacitidine and a placebo . (cancer.gov)
A positive overall survival outcome was achieved only in PD-L1 + TNBC patients, suggesting a need to enrich the patient population more likely to benefit from an immunotherapeutic approach. (biomedcentral.com)
11 ] demonstrated a substantial overall survival (OS) benefit in patients with PD-L1-positive (PD-L1 + ) metastatic or inoperable locally advanced TNBC through the addition of the anti-PD-L1 agent atezolizumab to first-line chemotherapy with nab-paclitaxel. (biomedcentral.com)
Approximately 60% of the enrolled patients (451 for each treatment arm) experienced relapse after prior adjuvant/neoadjuvant treatment, while 37% presented with de novo stage IV disease. (biomedcentral.com)
Additionally, approximately 41% of patients in the intent-to-treat (ITT) population had PD-L1 + disease. (biomedcentral.com)
These findings demonstrate 5-year overall survival of greater than 90% in patients with clinical stage IA, small-sized, peripheral NSCLC who receive curative-intent surgery. (universimed.com)
Despite none of the patients presented with neurological symptoms, occult CNS involvement was detected in 6/10 cases evaluated at diagnosis and 3/3 studied at relapse/progression. (ub.edu)
BPDCN patients evaluated at diagnosis received IT treatment -either CNS prophylaxis (n = 4) or active therapy (n = 6)- and all but one remain alive (median follow-up of 20 months). (ub.edu)
In contrast, all three patients assessed at relapse/progression died. (ub.edu)
The potential benefit of IT treatment administered early at diagnosis on OS and CNS recurrence-free survival of BPDCN was further confirmed in a retrospective cohort of another 23 BPDCN patients. (ub.edu)
Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
315 patients had PSA relapse after radical treatment, 33 patients had no prior local therapy. (lu.se)
Limitations were slow recruitment, lack of enrolling patients without radical local treatment, and too short follow-up for evaluation of overall survival in patients with PSA relapse. (lu.se)
Conclusion: Docetaxel improved PFS in patients starting bicalutamide due to PSA relapse after local therapy or localized disease without local therapy. (lu.se)
In 73% of patients on combo therapy, tumors shrank and 45% of these patients had no evidence of disease at time of surgery. (medpagetoday.com)
Two patients with progressive disease on monotherapy were unable to have definitive surgical resection after developing synchronous metastatic disease and local progression. (medpagetoday.com)
The inclusion of patients with stage IV oligometastatic disease was a study limitation, making the study participants "relatively heterogeneous," the authors noted, thereby decreasing the generalizability of the results to a stage III population. (medpagetoday.com)
Disease-free survival was the main outcome measure in the study, and patients were followed for a median duration of 55 months. (kanker-actueel.nl)
When enrollment was closed, 31.3% of patients in the XELOX group had relapsed, developed a new colon cancer, or died, compared with 37.5% of the FU/FA group. (kanker-actueel.nl)
We present an updated RFS analysis on the basis of extended study follow-up and a cure-rate model analysis to estimate the fraction of patients expected to remain relapse free long term. (edu.au)
The fraction of patients who remained relapse free long term was estimated using a Weibull mixture cure-rate model. (edu.au)
OBJECTIVES: To describe the morphologic characteristics of skin lesions, extent of extracutaneous disease, and outcomes in patients with neonatal presentation of Langerhans cell histiocytosis (LCH), and to examine clinical predictors of disease prognosis. (thedoctorsdoctor.com)
One third of patients had disease limited to the skin and/or mucous membranes. (thedoctorsdoctor.com)
Twelve of the 19 patients had multisystem disease, and 2 died of disease. (thedoctorsdoctor.com)
The results of a multiorgan workup performed at the time of diagnosis were predictive of which patients in this cohort manifested multisystem disease. (thedoctorsdoctor.com)
The association with thyroid disease in the proband was explained partially by the involvement of the pituitary, with the relative risk decreasing when patients with diabetes insipidus and thyroid involvement were excluded from analysis. (thedoctorsdoctor.com)
Hormonal treatment of advanced prostate cancer should be consideredfor patients who have stages C and D1 disease, a high risk of recurrenceafter local therapy, or prostate-specific antigen-measured recurrenceafter local treatment. (cancernetwork.com)
This would include notonly stage D2 patients, but also menwith stages C and D1 (T3, T4, andany T, N1) disease, a high risk of diseaserecurrence after local therapy, andprostate-specific antigen (PSA) recurrenceafter local therapy. (cancernetwork.com)
With this in mind, most HSCT research and treatment centers restrict the treatment to patients with active inflammatory MS, meaning that eligible patients must have recently experienced multiple MS relapses and/or displayed enhancing lesions on their MRI images (enhancing lesions are indicators of immune activity within the central nervous system). (wheelchairkamikaze.com)
Since this excludes many secondary progressive (SPMS) and most primary progressive (PPMS) patients, who experience increasing disability in the complete absence of relapses or enhancing lesions, these requirements are understandably the source of much consternation among this patient population (myself included), who are currently presented with no effective treatment options. (wheelchairkamikaze.com)
Not only did the vast majority of these patients see their disease stop in its tracks, but a large proportion also saw their levels of disability improve. (wheelchairkamikaze.com)
The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy. (curetoday.com)
This FDA approval was based on findings from the phase 2 MagnetisMM-3 trial, which assessed the efficacy of Elrexfio in 123 patients with heavily pretreated relapsed or refractory multiple myeloma. (curetoday.com)
Several outcomes had not yet been reached at follow-up including overall survival (the time from treatment assignment when a patient with cancer is alive), duration of response and progression-free survival (the time during and after treatment when a patient with cancer lives without disease worsening), meaning that the outcome did not occur in more than half of patients in the study. (curetoday.com)
Most multiple myeloma patients will experience relapse or resistance of their disease to treatment, often facing increased symptom burden and lowering their chance of surviving longer with each attempted line of therapy," MagnetisMM clinical trial investigator Dr. Ajay Nooka, director of the multiple myeloma program at Winship Cancer Institute of Emory University, said in the release. (curetoday.com)
Overall survival was 100%, and all 12 patients are disease-free with a median follow-up of 26 months. (elsevierpure.com)
The median patient age was 54.5 years (range: 23 to 73 years), and eight (67%) of the patients were female. (cdc.gov)
Eleven of the patients had TB disease after receiving infliximab. (cdc.gov)
Eleven of the patients had at least one risk factor for LTBI (e.g., born in countries where TB is prevalent or contact with a person with TB disease). (cdc.gov)
Thirty-one patients (9.5%) received ibrutinib as first-line therapy and the rest had relapsed/refractory disease and had previously received a median of three therapies. (medscape.com)
In all, 185 patients (56.6%) had bulky disease (lymph node of at least 5 cm) and 184 (56.3%) had advanced-stage disease. (medscape.com)
Oncologist Dr. Jennifer A. Woyach of The Ohio State University, in Columbus, told Reuters Health by email, "These retrospective data, as well as the studies showing longer progression-free survival for those patients receiving ibrutinib as earlier lines of therapy, suggest that we should be using ibrutinib in the front-line setting rather than saving it for a salvage therapy. (medscape.com)
The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)

Newer studies with intensive multiagent chemotherapy (eg, the CALGB [Cancer and Leukemia Group B]- 8811 and hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone] regimens and the ALL-2 regimen) plus the addition of TKIs for Ph+ ALL and rituximab for CD20-positive ALL have resulted in 3-y survivals of 50% or more in adults. (medscape.com)
The study will also evaluate the toxic effects of the chemotherapy combination, including effects on the heart, and will determine survival and progression-free survival 5 years after treatment. (stanford.edu)
It is not yet known whether chemotherapy is effective in treating women who have undergone surgery and radiation therapy for relapsed breast cancer. (stanford.edu)
PURPOSE: Randomized phase III trial to determine the effectiveness of adjuvant chemotherapy in treating women who have undergone resection for local and/or regional relapsed breast cancer. (stanford.edu)
The FLT3 inhibitors sorafenib, midostaurin, quizartinib and gilteritinib have been tested in monotherapy in several settings including refractory or relapsed AML (R/R AML), post-transplant maintenance as well as in combination with intensive chemotherapy (ICT) or non-intensity regimens. (dovepress.com)
If possible, people newly diagnosed with AML receive an intensive regimen of multiple chemotherapy drugs, with the goal of pushing the disease into a complete remission -that is, eliminating leukemia cells in the bone marrow . (cancer.gov)
In the present study the objective was to investigate if chemotherapy added to endocrine therapy could improve progression-free survival (PFS). (lu.se)
Conclusions: Chemotherapy with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine is well tolerated and highly effective for metastatic, high-risk gestational trophoblastic disease. (elsevierpure.com)
Treatment includes induction chemotherapy to achieve remission and postremission chemotherapy (with or without stem cell transplantation) to avoid relapse. (msdmanuals.com)

There is no clear definition of cure in metastatic disease. (springer.com)
In order to cure metastatic disease, several approaches are imaginable: (1) locoregional treatment of the primary tumor and all metastatic sites, (2) tumor eradication by excellent systemic anticancer therapy, (3) long-term immunologic tumor control induced by immunotherapy or (4) the combination of these approaches. (springer.com)
Of particular interest are adjuvant therapy, treatment of metastatic disease, methods for treatment of locally advanced breast cancer and inflammatory breast cancer. (stanford.edu)
Metastatic disease occurs in 16% of all RMS cases and has a poor prognosis. (stanfordchildrens.org)
Although pulmonary carcinoids show relatively good prognosis in comparison to carcinomas, metastatic disease and relapse do occur. (who.int)

Acute Graft-versus-host disease (GvHD), one of the major complications of HSCT, is correlated to conditioning-induced gut barrier damage and may be predicted by pre-transplant serum citrulline level (Rashidi, BBMT 2018). (confex.com)
Study end points were the probabilities of overall survival, leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM) and chronic graft- versus -host disease. (haematologica.org)
Adding sirolimus to a standard graft-versus-host disease (GVHD) prophylaxis of mycophenolate mofetil (MMF) and cyclosporine (CSP) can significantly reduce the risks of grades II-IV and III-IV acute GVHD and non-relapse mortality (NRM), according to results of a phase 3 multi-center randomized trial presented at ASH. (bethematchclinical.org)
PFS = progression-free survival, NRM = non-relapse mortality, GVHD = graft-versus-host disease. (bethematchclinical.org)

We report updated RFS (primary end point) and distant metastasis-free survival. (edu.au)

Median progression-free survival was not yet reached in the treatment-naive group and was 52 months in those with relapsed or refractory disease. (ascopost.com)

Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. (springer.com)
An antioxidant-rich extract of seaweed polyphenols combined with current PC treatment modalities may inhibit tumor relapse by targeting therapy-orchestrated autophagy in residual cells. (greenmedinfo.com)
Bristol-Myers Squibb), had stable disease or tumor shrinkage 12 weeks after treatment. (aacrjournals.org)
The intent of vaccination is to induce a combined antibody and T-cell anti-HER-2 immune response, which is intended to target HER-2-expressing tumor cells, and may induce tumor regression or slow progression of disease. (stanford.edu)
Without treatment, SCLC has the most aggressive clinical course of any type of pulmonary tumor, with a median survival from diagnosis of only 2 to 4 months. (cancer.gov)
At the epicenter of this dynamic and complex TME lies the cancer stem cell (CSC), which is believed to be the root of the tumor and the cell responsible for chemoresistance and disease relapse. (mdpi.com)

It could be interesting to know whether citrulline kinetics could also represent a biomarker for conditioning toxicity, non-relapse mortality (NRM), and GvHD. (confex.com)
The only factor associated with higher non-relapse mortality was patient gender (male: 27±6% vs . female: 10±5%, P =0.04). (haematologica.org)
Despite improvements in treatment options and survival outcomes in recent years, NZ ABC mortality rates continue to exceed the OECD average [ 1 ]. (hindawi.com)
Because the triple prophylactic regimen also reduced non-relapse mortality without increasing the risk of relapse or progressive malignancy, the researchers recommended that the regimen be considered in the future as the standard of care in adults undergoing minimal-intensity unrelated donor HCT. (bethematchclinical.org)

The authors state that complete remission and long-term PFS are usually surrogates for cure in metastatic cancer, but long-term survival might simply reflect an indolent nature of the disease rather than a long-term effect from therapy. (springer.com)

The median time to minor and major responses was 1.9 and 5.1 months, respectively. (nih.gov)
The median follow-up time was 33 months, and the median progression-free survival was 30 months. (nih.gov)
the median Progression-Free Survival was 9.4 months and the Duration of Response was 9.6 months. (wikipedia.org)
The median progression-free survival (PFS) was not reached with isatuximab vs 20.27 months with Kd (95% CI, 15.77-not reached). (onclive.com)
Median relapse-free survival, measured from the first documentation of CR to the date of relapse or death, was 11.6 months. (fda.gov)
median survival is less than 24 months 4 - 6 The best therapeutic option has not yet been established. (haematologica.org)
Median follow up was 48 months (range 6-213 months). (haematologica.org)
Median PFS was 3.6 months, the 1-year OS estimate was 50.6% (median not reached). (uni-koeln.de)
Median progression-free survival was 26 months for those with 17p deletion, 55 months for those with deletion 11q, 43 months for those with unmutated immunoglobulin heavy-chain variable region ( IGVH ), and not reached for those with deletion 13q. (ascopost.com)
the median progression-free survival (PFS) was 4 months with nivolumab alone and 5.6 months with the dual nivolumab/ipilimumab therapy. (aacrjournals.org)
Deep responses with uMRD were associated with superior progression-free survival (PFS) of VenR vs BR with 48 months (mo) follow-up (f/u). (confex.com)
Both groups received treatment every two weeks until disease progression or a maximum of 12 months, whichever occurred first. (curetoday.com)
The IRC-assessed median duration of response (DOR) was 34.3 months and median progression-free survival (PFS) was not reached. (businesswire.com)
After completion of radiotherapy, the primary site had no residual disease, but while on follow-up he developed left sided neck nodes within 4 months of completion of treatment. (bvsalud.org)
The median duration of treatment was 11.5 months with D-Pd versus 6.6 months with pomalidomide and the primary analysis performed after 190 PFS events. (pharmacytimes.com)
The median PFS for the D-Pd versus pomalidomide arms was 12.4 versus 6.9 months, respectively. (pharmacytimes.com)
However, a statistically significant median OS increase of 9.5 months was observed with the addition of atezolizumab in the PD-L1 + population (25.0 vs. 15.5 months). (biomedcentral.com)
Transplant outcomes at a median follow up of 24 months. (bethematchclinical.org)
The median follow-up was 15.6 months for the combo therapy arm and 15 months for the monotherapy arm. (medpagetoday.com)
The median time to first response to treatment was 1.2 months, according to the release. (curetoday.com)
In January 2002, a U.S.-born man aged 55 years with rheumatoid arthritis had pulmonary TB disease diagnosed 17 months after starting infliximab therapy. (cdc.gov)
The median time to complete response was 14.7 months. (medscape.com)
Taking alpha-lipoic acid by mouth daily for up to 6 months does not improve liver function or reduce liver damage in people with alcohol-related liver disease. (medlineplus.gov)

In the United States, melphalan flufenamide is indicated in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma, with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody. (wikipedia.org)
In the European Union, melphalan flufenamide is indicated, in combination with dexamethasone, for the treatment of adults with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. (wikipedia.org)
That's a very impressive PFS for a triplet therapy in relapsed or refractory multiple myeloma. (onclive.com)
Despite increasing knowledge, no major breakthrough in therapy has been observed in the last 30 years that would lead to long-term survival. (muni.cz)
This is very welcome and is set to continue as we increase our understanding of biology and evaluate more new exciting treatments, particularly in the relapsed setting where there remains a lack of FDA-approved therapy. (curetoday.com)
Myeloma/Amyloidosis: Therapy, excluding Transplantation: Relapsed/Refractory Multiple Myeloma. (pharmacytimes.com)
The trial planned for people to receive at least six monthly rounds of treatment, but participants could continue therapy as long as their disease remained under control. (cancer.gov)
Research in CAR T-cell therapy is expected to improve tolerability and expand indications to more types of malignancies and earlier phases of disease. (ajmc.com)
In BRAF-mutated melanoma, a previous small study by Wargo's group showed that targeted combination therapy before and after surgery for high-risk disease melanoma yielded a more than six-fold improvement in event-free survival (EFS) compared with surgery alone. (medpagetoday.com)
The Food and Drug Administration (FDA) approved Elrexfio (elranatamab-bcmm) to treat adults with relapsed or refractory multiple myeloma who previously received four or more lines of therapy. (curetoday.com)
Ovarian carcinoma is not a single disease entity and comprises various subtypes, each with distinct complex molecular landscapes that change during progression and therapy. (cdc.gov)
In 2002, a California county health department reported three cases of TB disease occurring in association with infliximab therapy. (cdc.gov)
One patient had TB disease while receiving chronic etanercept therapy. (cdc.gov)
Dr. Susan M. O'Brien of the University of California, Irvine, told Reuters Health by email, "Ibrutinib produces more complete (response) if given to people as initial therapy (as opposed to in relapse after prior therapy) and when they don't have bulky disease. (medscape.com)
All HIV-infected persons at risk for infection with M. tuberculosis must be carefully evaluated and, if indicated, administered therapy to prevent the progression of latent infection to active TB disease and avoid the complications associated with HIV-related TB. (cdc.gov)
In September 1997, CDC convened a meeting of expert consultants who reviewed and considered background information about HIV-related TB in the United States and the scientific principles of therapy for both diseases (Part I of this report). (cdc.gov)

The 3- and 5-year event-free survival was 9.4% and 8.2%, respectively. (stanfordchildrens.org)

A sub-study was introduced in 2018, allowing pts who developed progressive disease (PD) following Tx with BR or VenR to receive the MURANO VenR regimen. (confex.com)
This Kd regimen administered with 56 mg/m 2 KYPROLIS twice weekly is already approved in the U.S., European Union and other countries based on the primary analysis of progression-free survival (PFS) in the ENDEAVOR study. (amgen.com)
ENDEAVOR is the only study to demonstrate a survival benefit in a head-to-head comparison with a current standard of care regimen. (amgen.com)

Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years [abstract]. (medscape.org)
The median age was 12 years (2-14 years). (bvsalud.org)
Over the last 10 years, considerable evidence has highlighted the primary role of the immune system in influencing the disease course of TNBC. (biomedcentral.com)
At a median follow-up of 7.3 years, the greater number of deaths in the lobectomy group (83 vs. 58) was not the result of the primary NSCLC, but rather other cancers (including second primary lung cancer) and non-lung-cancer causes, including respiratory and cerebrovascular diseases. (universimed.com)
Median follow-up was 4.9 years (IQR 4.0-5.1). (lu.se)
MMF/CSP/sirolimus, n=84) with a median age of 62 years (range, 18-79). (bethematchclinical.org)
RESULTS: The median age at diagnosis of LCH was 1.8 years (range 0.1 to 14.6 years). (thedoctorsdoctor.com)
Four years after treatment, 80% of trial subjects remained relapse free, and 87% showed no signs of disease progression. (wheelchairkamikaze.com)
A woman aged 64 years with rheumatoid arthritis had pulmonary and pericardial TB disease diagnosed in June 2002. (cdc.gov)
With an average survival rate of three years, IBC accounts for about 2.5% of all breast cancer types in the US. (bvsalud.org)
it is the most common acute leukemia in adults, with a median age of onset of 68 years. (msdmanuals.com)
APL is a particularly important subtype, representing 10 to 15% of all cases of AML, striking a younger age group (median age 31 years) and particular ethnicity (Hispanics). (msdmanuals.com)
Results: Among 2.4 million participants, 58,785 developed lung cancer (median follow-up 12.6 years). (who.int)

CXCR4 mutations did not affect treatment response or progression-free survival. (nih.gov)
ABSTRACT Introduction: The perception of prejudice against, and stigmatization of, sickle cell disease (SCD) leads the patient to perceive a different treatment, due to the disease stigma and maybe related to a worse quality of life (QoL). (scielo.br)
Early death, rather than resistant disease so common in all other subtypes of AML, has emerged as the major cause of treatment failure. (nature.com)
Currently, there is no standard treatment for relapsed mesothelioma, although according to Mansfield vinorelbine is the most commonly used second-line agent. (aacrjournals.org)
The improvements in response rates and survival, however, came at a cost of more severe side effects, including three treatment-related deaths in the nivolumab plus ipilimumab arm. (aacrjournals.org)
As such, he said, "it is impossible to know what is treatment effect and what is indolent disease in this study because both arms received treatment. (aacrjournals.org)
Demographic, diagnostic, treatment, and survival data were extracted from electronic records for statistical analysis. (hindawi.com)
Median number of lines of systemic treatment was two, with similar treatment exposure between ethnic groups. (hindawi.com)
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. (businesswire.com)
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. (businesswire.com)
Disease-free survival correlated negatively with the maximum tissue-to-blood 18 F-fluoromisonidazole ratio (T/B max ) on the baseline 18 F-fluoromisonidazole scan ( P = 0.04), with the size of the initial hypoxic volume ( P = 0.04), and with T/B max on the 18 F-fluoromisonidazole scan during treatment ( P = 0.02). (snmjournals.org)
The primary endpoint of the trial was PFS, defined as the time from treatment initiation to disease progression or death. (amgen.com)
Median duration of injection was 5 minutes, and rates of study treatment discontinuation occurred due to treatment-emergent AEs were similar for D-Pd versus pomalidomide. (pharmacytimes.com)
moreover, they also indicate that treatment of occult CNS disease might lead to a dramatically improved outcome of BPDCN. (ub.edu)
Subgroup analysis of RFS demonstrated similar treatment benefit regardless of baseline factors, including disease stage, nodal metastatic burden, and ulceration. (edu.au)
Isoniazid was discontinued, and she was free of TB disease after treatment with rifampin, pyrazinamide, and ethambutol. (cdc.gov)
Of the 119studies identified, 25 complied with the eligibility criterion for the disease, diagnostics, treatment and prognostics. (bvsalud.org)
The goal of these policies is to establish collective guidelines to increase health and quality of life through prevention, treatment of disease and health behavior promotion 1 . (bvsalud.org)

The primary endpoint of IKEMA was progression free survival (PFS). (sanofi.com)

Future prospective studies are required to test different strategies that can improve the rates and quality (based on measurable residual disease [MRD] assessment) of remissions prior to and after allo-HCT using less toxic and more effective induction, conditioning, and maintenance therapies. (ascopost.com)
While effective, broad use of CAR T-cell therapies is limited by potential for life-threatening toxicities, challenges related to manufacturing a patient-specific product, high costs and inadequate reimbursement, and incomplete or unsustained disease response. (ajmc.com)
Confirmatory studies of the efficacy of docetaxel in the setting of PSA-only relapse in addition to endocrine therapies may be justified if longer follow-up will show increased metastatic-free survival. (lu.se)

We now report long-term MRD kinetics and updated efficacy outcomes, including re-exposure to VenR (to be presented), with a 5 year (yr) median follow-up (clinical cutoff date May 8, 2020). (confex.com)
They had clinical stage IIIB disease, stage IIIC disease, or oligometastatic stage IV disease. (medpagetoday.com)

In 1999 there were 2 major obstacles for curing adults with sickle cell disease. (nih.gov)
The first step was to provide a curative option for the majority of adults with SCD that are not eligible for the standard transplant because of age and co-morbidities including heart, lung, and kidney disease. (nih.gov)
The disease is now considered to be the most curable subtype of acute myeloid leukemia (AML) in adults. (nature.com)

Adrenocortical carcinoma (ACC) is a rare disease associated with a poor prognosis. (cancerindex.org)

Lead author Dr. Brenda Sandmaier of the Fred Hutchinson Cancer Research Center noted in her oral presentation that because an interim analysis revealed that the sirolimus arm had significantly lower acute GVHD and improved survival than the standard MMF/CSP arm, the trial was closed early. (bethematchclinical.org)
Complete response also was significantly associated with not having bulky disease (OR, 4.97). (medscape.com)

Most cases of myeloid sarcoma will develop within the first year preceding the occurrence of acute myeloid leukemia (AML), or concomitantly to AML, or at relapse of AML. (haematologica.org)

MRD [minimal residual disease] negativity was quite impressive, too, with the MRD-negativity rate sitting at around 40% in the intention-to-treat population. (onclive.com)

Statistically significant associations included the following: infections in the neonatal period (MS-LCH, odds ratio (OR) = 2.2), solvent exposure (SS-LCH, OR = 54.9), childhood vaccinations (MS-LCH and SS-LCH, OR = 0.4), thyroid disease in the proband (MS-LCH and SS-LCH, OR = 21.6), and family history of thyroid disease (MS-LCH and SS-LCH, OR = 1.4). (thedoctorsdoctor.com)

CONCLUSIONS: Vesiculopustular lesions are common in congenital/neonatal LCH, but the morphologic characteristics of lesions are not helpful in predicting the extent of disease. (thedoctorsdoctor.com)

A survival benefit has rarely been demonstrated in relapsed or refractory multiple myeloma. (amgen.com)

It has already been shown that PDAC is not a single disease but a very heterogeneous malignancy. (muni.cz)

He was referred to our center with residual disease in spheno-ethmoidal recess for which radiotherapy was given. (bvsalud.org)

These products work by blocking TNF-α, an inflammatory cytokine, and are approved for treating rheumatoid arthritis and other selected autoimmune diseases. (cdc.gov)

Anatomy7

Organisms4

Diseases58

Chemicals and Drugs49

Analytical, Diagnostic and Therapeutic Techniques and Equipment79

Phenomena and Processes23

Disciplines and Occupations1

Anthropology, Education, Sociology and Social Phenomena1

Information Science9

Named Groups2

Health Care35

Geographicals2

Patients137

Chemotherapy9

Metastatic disease5

Graft versus4

Metastasis-free1

Refractory disease1

Tumor6

Mortality4

Remission1

Months23

Therapy16

Event-free survival1

Regimen3

Years13

Treatment18

Primary endpoint1

Therapies3

Clinical2

Adults3

Prognosis1

Significantly2

Acute1

Minimal residua1

Statistically significant1

Lesions1

Multiple1

Malignancy1

Residual disease1

Autoimmune diseases1